rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Kurt Von Emster

Director

Company insider

Files Form 4 as: Director, Iambic Therapeutics; Director and 10% owner, Jasper Therapeutics; Director, CymaBay Therapeutics; Director, Vaxcyte; Director and 10% owner, Vera Therapeutics; Director, CRISPR Therapeutics AG; Director, Pernix Sleep; Director, Facet Biotech.

Every Form 4 they filed

In numbers

Trades disclosed
199
Buys
7
Sells
78
Bought
$12.2M
Sold
$76.5M
Companies
8
Companies where not an officer
8
First trade
15 Dec 2005
Last trade
14 Oct 2026
Last filed
16 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
IAM Iambic TherapeuticsDirector · last 14 Oct 20260 buys · 0 sells
JSPR Jasper TherapeuticsDirector, 10% owner · Biotechnology · last 31 Jul 20260 buys · 1 sell
CymaBay TherapeuticsDirector · last 22 Mar 20241 buy · 30 sells
PCVX VaxcyteDirector · Biotechnology · last 2 Jun 20211 buy · 0 sells
VERA Vera TherapeuticsDirector, 10% owner · Biotechnology · last 18 May 20212 buys · 0 sells
CRSP CRISPR Therapeutics AGDirector · Genomics & Gene Editing · last 18 Dec 20182 buys · 40 sells
Pernix SleepDirector · last 6 Mar 20131 buy · 7 sells
Facet BiotechDirector · last 21 Apr 20100 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
14 Oct 2026filed 16 Oct 2026IAM Iambic Therapeuticsoption or derivativeSEC FORM 4 Code A—20,300 at $0.00filing
31 Jul 2026filed 4 Aug 2026JSPR Jasper Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,500 at $0.00filing
31 Jul 2026filed 4 Aug 2026JSPR Jasper Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,500 at $0.00filing
3 Jul 2025filed 3 Jul 2025JSPR Jasper Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,500 at $0.00filing
6 Jun 2024filed 10 Jun 2024JSPR Jasper Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—7,500 at $0.00filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—9,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—9,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—9,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—15,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—7,500filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—16,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—27,705filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—49,245filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—32,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—67,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—25,000filing
22 Mar 2024filed 22 Mar 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code D—14,010filing
22 Mar 2024filed 22 Mar 2024CymaBay TherapeuticsSEC FORM 4 Code D—90,000filing
24 Jan 2024filed 26 Jan 2024CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code A—14,010 at $0.00filing
29 Sep 2023filed 29 Sep 2023CymaBay Therapeuticsoption or derivativeSEC FORM 4 Code M—6,357 at $0.00filing

Sectors

Health Care46
Not placed39

Buys in green, sells in red, by the company’s sector.

Related people

R. Jacob VogelsteinDirector · Director at Iambic Therapeutics, filing Form 4 there in the last year
Catalio Capital Management, LP10% owner · 10% owner at Iambic Therapeutics, filing Form 4 there in the last year
Michael SecoraCFO & Chief Corp Dev Ofcr · CFO & Chief Corp Dev Ofcr at Iambic Therapeutics, filing Form 4 there in the last year
Evan Lockwood RachlinDirector · Director at Iambic Therapeutics, filing Form 4 there in the last year
William H. RastetterDirector and Other role · Director and Other at Iambic Therapeutics, filing Form 4 there in the last year
Samarth KulkarniChief Executive Officer · Also traded CRSP in the last 90 days
James R. KasingerGeneral Counsel and Secretary · Also traded CRSP in the last 90 days
Simeon GeorgeDirector · Also traded CRSP in the last 90 days